DR. ROBERT M STOTE, M.D.
Osteopathic Medicine at Pasadena Point Blvd, Saint Petersburg, FL

License number
Florida ME 18559
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
6210 Pasadena Point Blvd S, Saint Petersburg, FL 33707
Phone
(727) 381-2203
(727) 344-1906 (Fax)

Personal information

See more information about ROBERT M STOTE at radaris.com
Name
Address
Phone
Robert Stote, age 85
6210 Pasadena Point Blvd S, Gulfport, FL 33707
Robert M Stote, age 85
6210 Pasadena Point Blvd S, Saint Petersburg, FL 33707

Professional information

Robert M Stote Photo 1

Dr. Robert M Stote - MD (Doctor of Medicine)

Hospitals:
6210 Pasadena Point Blvd S, Saint Petersburg 33707
6210 Pasadena Point Blvd S, Saint Petersburg 33707
Education:
Medical Schools
Albany Medical College
Graduated: 1964


Robert Stote Photo 2

Nasal Formulations Of Insulin

US Patent:
2009032, Dec 31, 2009
Filed:
Jun 5, 2009
Appl. No.:
12/479348
Inventors:
Robert Stote - Gulfport FL, US
Poul Strange - Princeton Junction NJ, US
Assignee:
CPEX Pharmaceuticals, Inc. - Exeter NH
International Classification:
A61K 49/00, A61K 38/28, A61P 3/10
US Classification:
424 92, 514 3
Abstract:
The present invention provides a method for achieving a therapeutically effective plasma levels of insulin by administering at least two doses of pharmaceutical formulation of insulin sequentially into the same nostril. The administration of the second dose in the same nostril gives substantially higher plasma levels of insulin when compared with sequential administration in two different nostrils. Without being limited to any specific physiological mechanism, it is believed that the first dose of insulin acts as a loading dose. This loading dose is required to achieve the subsequent plasma levels of insulin that are observed with subsequent doses. The Cmax of plasma insulin achieved by the methods and formulations of the present invention is at least about 70 microU/ml when plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose. The AUC achieved is at least about 1800 microU/(ml*min). When administered sequentially in the same nostril, the Cmax of plasma insulin after a second dose is about five-fold greater than the Cmax of plasma insulin observed after the first dose; note, plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose.